![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Craig J. Currie, Chris D. Poole & Natalie L. Papo. (2009) An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes. Current Medical Research and Opinion 25:10, pages 2389-2400.
Read now
Read now
Cecilia M Lansang & Laurence Kennedy. (2007) Insulin glargine: a basal insulin for the management of diabetes. Expert Review of Endocrinology & Metabolism 2:5, pages 573-585.
Read now
Read now
Phil McEwan, Chris D. Poole, Tony Tetlow, Paul Holmes & Craig J. Currie. (2007) Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion 23:sup1, pages S21-S31.
Read now
Read now
Articles from other publishers (16)
Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health 25:7, pages 1235-1252.
Crossref
Crossref
Kirsty Winkley, Rebecca Upsher, Daniel Stahl, Daniel Pollard, Architaa Kasera, Alan Brennan, Simon Heller & Khalida Ismail. (2020) Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technology Assessment 24:28, pages 1-232.
Crossref
Crossref
Tsung‐Ying Lee, Shihchen Kuo, Chen‐Yi Yang & Huang‐Tz Ou. (2020)
Cost‐effectiveness of long‐acting insulin analogues
vs
intermediate/long‐acting human insulin for type 1 diabetes: A population‐based cohort followed over 10 years
. British Journal of Clinical Pharmacology 86:5, pages 852-860.
Crossref
Crossref
Daniel M. Sugrue, Thomas Ward, Sukhvir Rai, Phil McEwan & Heleen G. M. van Haalen. (2019) Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. PharmacoEconomics 37:12, pages 1451-1468.
Crossref
Crossref
Dalia Dawoud, Elisabetta Fenu, Bernard Higgins, David Wonderling & Stephanie A. Amiel. (2017) Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis. Value in Health 20:10, pages 1279-1287.
Crossref
Crossref
Simon Heller, David White, Ellen Lee, Julia Lawton, Daniel Pollard, Norman Waugh, Stephanie Amiel, Katharine Barnard, Anita Beckwith, Alan Brennan, Michael Campbell, Cindy Cooper, Munyaradzi Dimairo, Simon Dixon, Jackie Elliott, Mark Evans, Fiona Green, Gemma Hackney, Peter Hammond, Nina Hallowell, Alan Jaap, Brian Kennon, Jackie Kirkham, Robert Lindsay, Peter Mansell, Diana Papaioannou, David Rankin, Pamela Royle, W Henry Smithson & Carolin Taylor. (2017) A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technology Assessment 21:20, pages 1-278.
Crossref
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Crossref
George Grunberger. (2014) Insulin Analogs—Are They Worth It? Yes!. Diabetes Care 37:6, pages 1767-1770.
Crossref
Crossref
P. Thokala, J. Kruger, A. Brennan, H. Basarir, A. Duenas, A. Pandor, M. Gillett, J. Elliott & S. Heller. (2014) Assessing the cost-effectiveness of Type?1 diabetes interventions: the Sheffield Type?1 Diabetes Policy Model. Diabetic Medicine 31:4, pages 477-486.
Crossref
Crossref
Karel KostevFranz-Werner Dippel & Ralph Bierwirth. (2013) Resource Consumption and Costs of Treatment in Patients with Type 1 Diabetes under Intensified Conventional Therapy under German Real-Life Conditions. Journal of Diabetes Science and Technology 7:3, pages 736-742.
Crossref
Crossref
Ernst-Günther Hagenmeyer, Katharina C Koltermann, Franz-Werner Dippel & Peter K Schädlich. (2011) Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review. Cost Effectiveness and Resource Allocation 9:1, pages 15.
Crossref
Crossref
Cosimo Giannini, Angelika Mohn & Francesco Chiarelli. (2009) Technology and the issue of cost/benefit in diabetes. Diabetes/Metabolism Research and Reviews 25:S1, pages S34-S44.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:4, pages 383-400.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
Crossref
. (2013) Insulin glargine adds up to value for diabetes in the UK. PharmacoEconomics & Outcomes News 528:1, pages 3-4.
Crossref
Crossref